File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.neuropharm.2004.10.018
- Scopus: eid_2-s2.0-13844275277
- PMID: 15721175
- WOS: WOS:000227622600012
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Ascorbic acid inhibits ROS production, NF-κB activation and prevents ethanol-induced growth retardation and microencephaly
Title | Ascorbic acid inhibits ROS production, NF-κB activation and prevents ethanol-induced growth retardation and microencephaly |
---|---|
Authors | |
Keywords | Ascorbic acid Ethanol Fetal development Xenopus laevis |
Issue Date | 2005 |
Publisher | Pergamon. The Journal's web site is located at http://www.elsevier.com/locate/neuropharm |
Citation | Neuropharmacology, 2005, v. 48 n. 3, p. 426-434 How to Cite? |
Abstract | In this study, we established an embryo model to study the effects of ethanol on fetal development. When embryos of Xenopus laevis (the African clawed frog) were exposed to ethanol, the resultant tadpoles had significantly reduced brain sizes (microencephaly) and retarded growth rates. These effects, similar to those observed in human fetal alcohol syndrome (FAS), were dose- and time-dependent. We further showed that the antioxidant ascorbic acid (vitamin C) could inhibit the ethanol-induced reactive oxygen species (ROS) production and NF-κB activation and protect the ethanol-treated embryos against microencephaly and growth retardation. These results suggest the involvement of NF-κB and oxidative stress in ethanol-mediated developmental defects, and the potential use of ascorbic acid as a new and effective protective agent for FAS. © 2004 Elsevier Ltd. All rights reserved. |
Persistent Identifier | http://hdl.handle.net/10722/167893 |
ISSN | 2023 Impact Factor: 4.6 2023 SCImago Journal Rankings: 1.489 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Peng, Y | en_HK |
dc.contributor.author | Kwok, KHH | en_HK |
dc.contributor.author | Yang, PH | en_HK |
dc.contributor.author | Ng, SSM | en_HK |
dc.contributor.author | Liu, J | en_HK |
dc.contributor.author | Wong, OG | en_HK |
dc.contributor.author | He, ML | en_HK |
dc.contributor.author | Kung, HF | en_HK |
dc.contributor.author | Lin, MCM | en_HK |
dc.date.accessioned | 2012-10-08T03:12:37Z | - |
dc.date.available | 2012-10-08T03:12:37Z | - |
dc.date.issued | 2005 | en_HK |
dc.identifier.citation | Neuropharmacology, 2005, v. 48 n. 3, p. 426-434 | en_HK |
dc.identifier.issn | 0028-3908 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/167893 | - |
dc.description.abstract | In this study, we established an embryo model to study the effects of ethanol on fetal development. When embryos of Xenopus laevis (the African clawed frog) were exposed to ethanol, the resultant tadpoles had significantly reduced brain sizes (microencephaly) and retarded growth rates. These effects, similar to those observed in human fetal alcohol syndrome (FAS), were dose- and time-dependent. We further showed that the antioxidant ascorbic acid (vitamin C) could inhibit the ethanol-induced reactive oxygen species (ROS) production and NF-κB activation and protect the ethanol-treated embryos against microencephaly and growth retardation. These results suggest the involvement of NF-κB and oxidative stress in ethanol-mediated developmental defects, and the potential use of ascorbic acid as a new and effective protective agent for FAS. © 2004 Elsevier Ltd. All rights reserved. | en_HK |
dc.language | eng | en_US |
dc.publisher | Pergamon. The Journal's web site is located at http://www.elsevier.com/locate/neuropharm | en_HK |
dc.relation.ispartof | Neuropharmacology | en_HK |
dc.subject | Ascorbic acid | en_HK |
dc.subject | Ethanol | en_HK |
dc.subject | Fetal development | en_HK |
dc.subject | Xenopus laevis | en_HK |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Ascorbic Acid - Pharmacology - Therapeutic Use | en_US |
dc.subject.mesh | Ethanol - Antagonists & Inhibitors - Toxicity | en_US |
dc.subject.mesh | Fetal Growth Retardation - Chemically Induced - Prevention & Control | en_US |
dc.subject.mesh | Microcephaly - Chemically Induced - Prevention & Control | en_US |
dc.subject.mesh | Nf-Kappa B - Antagonists & Inhibitors - Metabolism | en_US |
dc.subject.mesh | Reactive Oxygen Species - Antagonists & Inhibitors - Metabolism | en_US |
dc.subject.mesh | Xenopus Laevis | en_US |
dc.title | Ascorbic acid inhibits ROS production, NF-κB activation and prevents ethanol-induced growth retardation and microencephaly | en_HK |
dc.type | Article | en_HK |
dc.identifier.email | Ng, SSM: ssmng@hku.hk | en_HK |
dc.identifier.email | Lin, MCM: mcllin@hkucc.hku.hk | en_HK |
dc.identifier.authority | Ng, SSM=rp00767 | en_HK |
dc.identifier.authority | Lin, MCM=rp00746 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1016/j.neuropharm.2004.10.018 | en_HK |
dc.identifier.pmid | 15721175 | - |
dc.identifier.scopus | eid_2-s2.0-13844275277 | en_HK |
dc.identifier.hkuros | 105168 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-13844275277&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 48 | en_HK |
dc.identifier.issue | 3 | en_HK |
dc.identifier.spage | 426 | en_HK |
dc.identifier.epage | 434 | en_HK |
dc.identifier.isi | WOS:000227622600012 | - |
dc.publisher.place | United Kingdom | en_HK |
dc.identifier.scopusauthorid | Peng, Y=7403419265 | en_HK |
dc.identifier.scopusauthorid | Kwok, KHH=7102194193 | en_HK |
dc.identifier.scopusauthorid | Yang, PH=24340289000 | en_HK |
dc.identifier.scopusauthorid | Ng, SSM=7403358718 | en_HK |
dc.identifier.scopusauthorid | Liu, J=36014680100 | en_HK |
dc.identifier.scopusauthorid | Wong, OG=7004813981 | en_HK |
dc.identifier.scopusauthorid | He, ML=35080389700 | en_HK |
dc.identifier.scopusauthorid | Kung, HF=7402514190 | en_HK |
dc.identifier.scopusauthorid | Lin, MCM=7404816359 | en_HK |
dc.identifier.issnl | 0028-3908 | - |